Screener
Liquidia Corporation LQDA Q2 2026 earnings
Reported August 12, 2026 · Before market open
Revenue$171.7MBeat by $3.2M
EPS$0.74Miss by $0.02
Revenue estimate$168.5M
EPS estimate$0.76
“We are pleased by the sustained adoption of YUTREPIA as the inhaled prostacyclin of choice. The inhaled category has grown almost 40% since launch, and YUTREPIA has captured an ever-increasing share of that growth. We are building on that momentum by strengthening the clinical evidence for YUTREPIA in PAH and PH-ILD patients transitioning from other therapies, and advancing studies in new indications that may broaden its impact. Having reset the bar for tolerability and dose flexibility with YUTREPIA, we are excited to have begun site activation and enrollment in Re-Spire, our pivotal study for L606, which we believe can raise that bar even further, beyond any therapy currently available or in development.”
Next report
Nov 2, 2026 (in a month)Revenue estimate$205.9M
EPS estimate$0.90
Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Liquidia Corporation report Q2 2026 earnings?
- Liquidia Corporation (LQDA) reported Q2 2026 earnings on August 12, 2026 before market open.
- What were Liquidia Corporation's Q2 2026 revenue and EPS?
- Liquidia Corporation reported revenue of $171.7M and eps of $0.74 for Q2 2026.
- Did Liquidia Corporation beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $168.5M by $3.2M. EPS missed the consensus estimate of $0.76 by $0.02.
- How did Liquidia Corporation's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 1842.7% from $8.8M a year earlier.
- Where can I find Liquidia Corporation's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-094411) and the 10-Q periodic report (0001104659-26-094410) directly on SEC EDGAR. The filing index links above go to sec.gov.
